Effects of ketamine on exocytotic and non-exocytotic noradrenaline release

Neurochemistry International

Volumn 42, Issue 3, 2003, Pages 261-267

  Kitagawa, Hirotoshi ^a,c   Yamazaki, Toji ^b   Akiyama, Tsuyoshi ^b   Mori, Hidezo ^b   Sunagawa, Kenji ^b  

^a NAGAHAMA CITY HOSPITAL   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Cat; Exocytosis; Heart; Membrane noradrenaline transport; Sympathetic nerve

Indexed keywords

DESIPRAMINE; KETAMINE; NORADRENALIN; OMEGA CONOTOXIN; OUABAIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIALYSATE LEVEL; DOSE RESPONSE; DRUG EFFECT; ELECTROSTIMULATION; EXOCYTOSIS; FEMALE; MALE; NERVE ENDING; NONHUMAN; NORADRENALIN RELEASE; NORADRENALIN UPTAKE; PRIORITY JOURNAL; STELLATE GANGLION; SYMPATHETIC NERVE; SYMPATHETIC TONE;

ANIMALS; CATS; ELECTRIC STIMULATION; EXOCYTOSIS; KETAMINE; NEURONS; NOREPINEPHRINE; OUABAIN;

FELIS CATUS; STROPHANTHUS GRATUS;

EID: 0037290230     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(02)00090-6     Document Type: Article

References (28)

1. Akiyama T., Yamazaki T. Norepinephrine release from cardiac sympathetic nerve endings in the in vivo ischemic region. J. Cardiovasc. Pharmocol. 34(Suppl. 4):1999;S11-14.
2. Akiyama T., Yamazaki T., Ninomiya I. In vivo monitoring of myocardial interstitial norepinephrine by dialysis technique. Am. J. Physiol. 261:1991;H1643-H1647.
3. + channels. Eur. J. Pharmacol. 25:1989;327-335.
4. Apple E., Dudziak R., Palm D., Wnuk A. Sympathoneuronal and sympathoadrenal activation during ketamine anesthesia. Eur. J. Clin. Pharmacol. 16:1979;91-95.
5. Bönisch, H., Trendelenburg, U., 1988. Mechanism of action of indirectly acting sympathomimetic amines. In: Trendelenburg, U., Weiner, N. (Eds.), Handbook of Experimental Pharmacology, Vol. 90/1. Catecholamine 1, Springer, Berlin, pp. 246-277.
6. Brau M.E., Sander F., Vogel W., Hempelmann G. Blocking mechanisms of ketamine and its enantiomers in enzymatically demyelinated peripheral nerve as revealed by single-channel experiments. Anesthesiology. 86:1997;394-404.
7. Cook D.J., Housmans P.R., Rorie D.K. Effect of ketamine HCL on norepinephrine disposition in isolated ferret ventricular myocardium. J. Pharmacol. Exp. Ther. 261:1992;101-107.
8. Eisenhofer G., Smolich J.J., Cox H.S., Esler M.D. Neuronal reuptake of norepinephrine and production of dihydroxyphenylglycol by cardiac sympathetic nerves in the anesthetized dogs. Circulation. 84:1991;1354-1363.
9. Hancock P.J., Stamford J.A. Stereospecific effects of ketamine on dopamine efflux and uptake in the rat nucleus accumbens. Br. J. Anaesth. 82:1999;603-608.
10. Hara K., Yanagihara N., Minami K., Ueno S., Toyohira Y., Sata T., Kawamura M., Bruss M., Bonish H., Shigematsu A., Izumi F. Ketamine interacts with the noradrenaline transporter at a site partly overlapping the desipramine binding site. Naunyn Schmiedebergs Arch. Pharmacol. 358:1998;328-333.
11. Hirota K., Kudo M., Kudo T., Kitayama M., Kushikata T., Lambert D.G., Matsuki A. Barbiturates inhibit K(+)-evoked noradrenaline and dopamine release from rat striatal slices - involvement of voltage sensitive Ca(2+) channels. Neurosci. Lett. 291:2000;175-178.
12. Kienbaum P., Heuter T., Michel M.C., Peters J. Racemic ketamine decreases muscle sympathetic activity but maintains the neuronal response to hypotensive challenges in humans. Anesthesiology. 92:2000;94-101.
13. Kitagawa H., Akiyama T., Yamazaki T. Myocardial interstitial noradrenaline monitoring during occlusion of inferior vena cava in cats. Acta Physiol. Scand. 163:1998;173-179.
14. Nishimura M., Sato K. Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci. Lett. 272:1999;131-134.
15. Maekawa M., Murayama T., Nomura Y. Involvement of noradrenaline transports in S-nitrosocysteine-stimulated noradrenaline release from rat brain slices: existence of functional Na(+)-independent transport activity. Neurochem. Int. 38:2001;323-331.
16. +-ATPase inhibitor. Comparison with ouabain Neurochem. Int. 39:2001;301-310.
17. Saegusa K., Furukawa Y., Ogiwara Y., Chiba S. Pharmacologic analysis of ketamine-induced cardiac actions in isolated, blood-perfused canine atria. J. Cardiovasc. Pharmacol. 8:1986;414-419.
18. Sasao J., Taneyama C., Kohno N., Goto H. The effects of ketamine on renal sympathetic nerve activity and phrenic nerve activity in rabbits (with vagotomy) with and without afferent inputs from peripheral receptors. Anesth. Analg. 82:1996;362-367.
19. 3H ]noradrenaline by veratridine and ishcmeia in spinal cord Neurochem. Int. 39:2001;59-63.
20. Sweadner K.J. Ouabain-evoked norepinephrine release from intact rat sympatheic neurons: evidence for carrier-mediated release. J. Neurosci. 9:1985;2397-2406.
21. Takauchi Y., Yamazaki T., Akiyama T. Tyramine-induced endogenous noradrenaline efflux from in situ cardiac sympathetic nerve ending in cats. Acta Physiol. Scand. 168:2000;287-293.
22. + activated adnosinetriphosphate as a trigger in transmitter release. Neuroscience. 3:1978;367-384.
23. Winer, B.J., 1971. Statistical Principles in Experimental Design, 2nd Edition. McGraw-Hill, New York.
24. Yahagi N., Akiyama T., Yamazaki T. Effects of ω-conotoxin GVIA on cardiac sympathetic nerve function. J. Auton. Nerv. Syst. 68:1998;43-48.
25. Yamazaki T., Akiyama T., Shindo T. Routine high-performance liquid chromatographic determination of myocardial interstitial norepinephrine. J. Chromatogr. B Biomed. Appl. 670:1995;328-331.
26. Yamazaki T., Akiyama T., Kitagawa H., Takauchi Y., Kawada T., Sunagawa K. A new, concise dialysis approach to assessment of cardiac sympathetic nerve terminal abnormalities. Am. J. Physiol. 272:1997;H1182-H1187.
27. Yamazaki T., Kawada T., Akiyama T., Kitagawa H., Takauchi Y., Yahagi N., Sunagawa K. ω-Conotoxin GVIA and desipramine insensitive norepinephrine efflux from cardiac sympathetic nerve terminal. Brain Res. 761:1997;329-332.
28. Yamazaki T., Akiyama T., Kawada T. Effects of ouabain on in situ cardiac sympathetic nerve endings. Neurochem. Int. 35:1999;439-445.